

# STATE OF NEW YORK

8824

## IN ASSEMBLY

January 12, 2022

Introduced by M. of A. GALLAGHER -- read once and referred to the  
Committee on Consumer Affairs and Protection

AN ACT to amend the general business law, in relation to requiring  
prescription drug manufacturers to notify the attorney general of  
arrangements between pharmaceutical manufacturers resulting in the  
delay of the introduction of generic drugs

The People of the State of New York, represented in Senate and Assem-  
bly, do enact as follows:

1 Section 1. This act shall be known and may be cited as the "manufac-  
2 turer disclosure and transparency act".

3 § 2. The general business law is amended by adding a new section 396-  
4 rrr to read as follows:

5 § 396-rrr. Delay of introduction of generic medications. 1. (a) Each  
6 pharmaceutical manufacturer doing business in this state that manufac-  
7 tures a brand name prescription drug and enters into an arrangement,  
8 through agreement or otherwise, with another pharmaceutical manufacturer  
9 that has the purpose or effect of delaying or preventing such other  
10 manufacturer from introducing a generic substitute for such drug into  
11 the marketplace shall, not later than thirty days after entering into  
12 such arrangement, send notice to the attorney general, in a form and  
13 manner prescribed by the attorney general, disclosing the name of such  
14 drug, the wholesale price, the disease such drug is commonly prescribed  
15 to treat, the manufacturer of such drug, the name of the generic  
16 manufacturer, and the length of the delay.

17 (b) The attorney general shall, no later than thirty days after  
18 receiving a notice pursuant to paragraph (a) of this subdivision, share  
19 the information with the drug utilization review board established under  
20 section three hundred sixty-nine-bb of the social services law, all  
21 medicaid managed care plans, health carriers and pharmacy benefits  
22 managers doing business in the state in a format and manner prescribed  
23 by the attorney general.

24 2. The office of the attorney general shall post on its website all  
25 the notices required pursuant to paragraph (a) of subdivision one of  
26 this section in a format and manner developed by the attorney general

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD02926-01-1

1 that is searchable by drug, cost, disease, and manufacturer both for the  
2 brand and generic drug for public review.

3 3. For a violation by a manufacturer of a brand name drug who knowing-  
4 ly or negligently fails to notify the attorney general as required in  
5 paragraph (a) of subdivision one of this section, the attorney general  
6 shall fine such manufacturer no less than five thousand dollars for the  
7 first violation for each day such manufacturer fails to properly notify  
8 the attorney general pursuant to the requirements of this section and no  
9 less than ten thousand dollars for each violation thereafter for each  
10 day such manufacturer fails to properly notify the attorney general  
11 pursuant to the requirements of this section.

12 4. The attorney general is authorized to promulgate rules and regu-  
13 lations necessary for the implementation of this section.

14 § 3. This act shall take effect on the one hundred eightieth day after  
15 it shall have become a law.